CNCE - コンサ―ト・ファ―マシュ―ティカルズ (Concert Pharmaceuticals Inc.)

CNCEのニュース

   Concert Pharmaceuticals to Webcast Presentation at UBS Virtual Healthcare Conference  2020/05/12 11:00:00 Business Wire
LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #CNCE--Concert will present a corporate overview at the 2020 UBS Virtual Global Healthcare Conference on May 19, 2020 at 3:00 p.m. ET.
   Concert Pharmaceuticals (CNCE) Reports Q1 Loss, Lags Revenue Estimates  2020/04/30 12:45:07 Zacks Investment Research
Concert (CNCE) delivered earnings and revenue surprises of 5.41% and -65.00%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
   Concert Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Update on Clinical Programs  2020/04/30 11:00:00 Business Wire
LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #CNCE--Concert will host a conference call and webcast April 30, 2020, at 8:30 a.m. ET to provide an update on the Company and discuss first quarter results.
   Concert Pharmaceuticals to Report First Quarter 2020 Financial Results on April 30, 2020  2020/04/23 11:00:00 Business Wire
LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #CNCE--Concert will report its first quarter 2020 financial results and host a conference call and webcast on April 30, 2020.
   Why Concert Pharmaceuticals (CNCE) Stock Might be a Great Pick  2020/04/15 12:55:00 Zacks Investment Research
Concert Pharmaceuticals (CNCE) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well
   Concert Pharmaceuticals Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares  2020/01/30 21:01:00 Business Wire
LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #CNCE--Concert announces closing of public offering and full exercise of underwriters’ option to purchase additional shares.
   Concert Pharmaceuticals Announces Pricing of Public Offering  2020/01/28 14:00:00 Business Wire
LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #CNCE--Concert Pharmaceuticals Announces Pricing of Public Offering
   Concert Pharmaceuticals Announces Proposed Public Offering of Common Stock  2020/01/27 21:02:00 Business Wire
LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #CNCE--Concert intends to offer and sell shares of its common stock in an underwritten registered public offering.
   Concert Pharmaceuticals Announces Notice of Allowance for U.S. Patent Application Related to CTP-543, Lead Candidate for Treatment of Alopecia Areata  2020/01/22 13:40:00 Business Wire
LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #Aim2TreatAlopeciaAreata--Concert received a Notice of Allowance from the USPTO for a patent application related to CTP-543 for alopecia areata.
   Concert Pharmaceuticals Successfully Completes Open Label Trial of CTP-543 in Patients with Alopecia Areata  2019/12/19 21:05:00 Business Wire
LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #Aim2TreatAlopeciaAreata--Results in the 8 mg twice-daily arm were consistent with the previously-reported 8 mg twice-daily results from the Company’s Phase 2 trial of CTP-543.
   Concert Pharmaceuticals Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares  2020/01/30 21:01:00 Business Wire
LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #CNCE--Concert announces closing of public offering and full exercise of underwriters’ option to purchase additional shares.
   Concert Pharmaceuticals Announces Pricing of Public Offering  2020/01/28 14:00:00 Business Wire
LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #CNCE--Concert Pharmaceuticals Announces Pricing of Public Offering
   Concert Pharmaceuticals Announces Proposed Public Offering of Common Stock  2020/01/27 21:02:00 Business Wire
LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #CNCE--Concert intends to offer and sell shares of its common stock in an underwritten registered public offering.
   Concert Pharmaceuticals Announces Notice of Allowance for U.S. Patent Application Related to CTP-543, Lead Candidate for Treatment of Alopecia Areata  2020/01/22 13:40:00 Business Wire
LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #Aim2TreatAlopeciaAreata--Concert received a Notice of Allowance from the USPTO for a patent application related to CTP-543 for alopecia areata.
   Concert Pharmaceuticals Successfully Completes Open Label Trial of CTP-543 in Patients with Alopecia Areata  2019/12/19 21:05:00 Business Wire
LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #Aim2TreatAlopeciaAreata--Results in the 8 mg twice-daily arm were consistent with the previously-reported 8 mg twice-daily results from the Company’s Phase 2 trial of CTP-543.

calendar